Sarepta has always been a strange one albeit interesting. A long long time with no drug to it's name a name change board bickering, FDA advisory board voted the drug down start of year, patients kicked up, FDA asked more data & eventually approved although still somewhat controversial. Anyway they have money now, well hopefully pending CR outcome. Their ex Chairman was also recently appointed NED on another ASX bio.
Ann: Cell-Penetrating Phylomers Improve Delivery of Drugs-PYC.AX, page-84
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.27 |
Change
0.005(0.40%) |
Mkt cap ! $740.7M | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.29 | $1.27 | $406.0K | 319.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13987 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 1380 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |